Literature DB >> 27879211

Generation of a human induced pluripotent stem cell (iPSC) line from a patient carrying a P33T mutation in the PDX1 gene.

Xianming Wang1, Shen Chen2, Ingo Burtscher3, Michael Sterr3, Anja Hieronimus4, Fausto Machicao5, Harald Staiger6, Hans-Ulrich Häring4, Gabriele Lederer7, Thomas Meitinger8, Heiko Lickert9.   

Abstract

Homozygous loss-of-function mutations in the gene coding for the homeobox transcription factor PDX1 leads to pancreatic agenesis, whereas certain heterozygous point mutations are associated with Maturity-Onset Diabetes of the Young 4 (MODY4) and Type 2 Diabetes Mellitus (T2DM). To understand the pathomechanism of MODY4 and T2DM, we have generated iPSCs from a woman with a P33T heterozygous mutation in the transactivation domain of PDX1. The resulting PDX1 P33T iPSCs generated by episomal reprogramming are integration-free, have a normal karyotype and are pluripotent in vitro and in vivo. Taken together, this iPSC line will be useful to study diabetes pathomechanisms.
Copyright © 2016 Helmholtz Zentrum München. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27879211     DOI: 10.1016/j.scr.2016.08.004

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  9 in total

Review 1.  Modeling different types of diabetes using human pluripotent stem cells.

Authors:  Essam M Abdelalim
Journal:  Cell Mol Life Sci       Date:  2020-11-26       Impact factor: 9.261

Review 2.  iPSC technology-based regenerative therapy for diabetes.

Authors:  Yasushi Kondo; Taro Toyoda; Nobuya Inagaki; Kenji Osafune
Journal:  J Diabetes Investig       Date:  2017-07-29       Impact factor: 4.232

3.  Point mutations in the PDX1 transactivation domain impair human β-cell development and function.

Authors:  Xianming Wang; Michael Sterr; Ingo Burtscher; Anika Böttcher; Julia Beckenbauer; Johanna Siehler; Thomas Meitinger; Hans-Ulrich Häring; Harald Staiger; Filippo M Cernilogar; Gunnar Schotta; Martin Irmler; Johannes Beckers; Christopher V E Wright; Mostafa Bakhti; Heiko Lickert
Journal:  Mol Metab       Date:  2019-03-20       Impact factor: 7.422

4.  Episomal Induced Pluripotent Stem Cells: Functional and Potential Therapeutic Applications.

Authors:  Aline Yen Ling Wang; Charles Yuen Yung Loh
Journal:  Cell Transplant       Date:  2019-11-14       Impact factor: 4.064

Review 5.  Stem Cell-Derived β Cells: A Versatile Research Platform to Interrogate the Genetic Basis of β Cell Dysfunction.

Authors:  Alberto Bartolomé
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

Review 6.  Human Pluripotent Stem Cells Go Diabetic: A Glimpse on Monogenic Variants.

Authors:  Sandra Heller; Michael Karl Melzer; Ninel Azoitei; Cécile Julier; Alexander Kleger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

Review 7.  Genome Editing Human Pluripotent Stem Cells to Model β-Cell Disease and Unmask Novel Genetic Modifiers.

Authors:  Matthew N George; Karla F Leavens; Paul Gadue
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-02       Impact factor: 6.055

8.  Genome-wide analysis of PDX1 target genes in human pancreatic progenitors.

Authors:  Xianming Wang; Michael Sterr; Ingo Burtscher; Shen Chen; Anja Hieronimus; Fausto Machicao; Harald Staiger; Hans-Ulrich Häring; Gabriele Lederer; Thomas Meitinger; Filippo M Cernilogar; Gunnar Schotta; Martin Irmler; Johannes Beckers; Martin Hrabě de Angelis; Michael Ray; Christopher V E Wright; Mostafa Bakhti; Heiko Lickert
Journal:  Mol Metab       Date:  2018-01-31       Impact factor: 7.422

Review 9.  Modeling Maturity Onset Diabetes of the Young in Pluripotent Stem Cells: Challenges and Achievements.

Authors:  Carmel Braverman-Gross; Nissim Benvenisty
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-22       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.